19-norandrostenedione

Identification

Name
19-norandrostenedione
Accession Number
DB01434
Type
Small Molecule
Groups
Experimental, Illicit
Description

19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.

Structure
Thumb
Synonyms
  • 4-estrene-3,17-dione
  • delta4-Estrene-3,17-dione
  • NOR
External IDs
NSC-12164
International/Other Brands
19-N-Andro / Bolandione / Proven Pure 19-Norandrostenedione
Categories
UNII
U90987PVU5
CAS number
734-32-7
Weight
Average: 272.382
Monoisotopic: 272.177630012
Chemical Formula
C18H24O2
InChI Key
JRIZOGLBRPZBLQ-QXUSFIETSA-N
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1
IUPAC Name
(1S,2R,10R,11S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
SMILES
[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]]1([H])[[email protected]@]3([H])CCC(=O)C=C3CC[[email protected]@]21[H]

Pharmacology

Indication

The claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

19-Norandrostenedione may be metabolized to 19-nortestosterone in both men and women. 19-Norandrostenedione, also known as nandrolone, is the basic substance of some very popular injectable anabolic steroids, however 19-norandrostenedione is not metabolized to testosterone. Whether or not increases in 19-nortestosterone levels would be sustained long enough by taking 19-norandrostenedione to show an increase in nitrogen retention and muscle strength and mass is unknown.

19-Norandrostenedione has also been shown to bind to androgen receptors with high selectivity. Transactivation of androgen receptor dependent reporter gene expression was 10 times lower than that produced by dihydrotestosterone. [1]

Absorption

Absorption appears variable, but some absorption does occur.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with 19-norandrostenedione.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with 19-norandrostenedione.Approved, Withdrawn
Aldesleukin19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of 19-norandrostenedione can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with 19-norandrostenedione.Experimental
AloglutamolThe bioavailability of 19-norandrostenedione can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with 19-norandrostenedione.Experimental
AluminiumThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione.Approved
AmiodaroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin B19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with 19-norandrostenedione.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with 19-norandrostenedione.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with 19-norandrostenedione.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione.Approved, Investigational
AprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with 19-norandrostenedione.Experimental
Bendroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with 19-norandrostenedione.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with 19-norandrostenedione.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with 19-norandrostenedione.Experimental
Bismuth SubcitrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with 19-norandrostenedione.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with 19-norandrostenedione.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with 19-norandrostenedione.Experimental
Bumetanide19-norandrostenedione may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of 19-norandrostenedione can be decreased when combined with Calcium silicate.Experimental
Capromab pendetide19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.Approved, Investigational
Ceritinib19-norandrostenedione may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione.Approved, Vet Approved
Chlorothiazide19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
Chlorthalidone19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 19-norandrostenedione.Approved
CinoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with 19-norandrostenedione.Investigational
Cyclopenthiazide19-norandrostenedione may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with 19-norandrostenedione.Investigational
DaidzeinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Daidzein.Experimental
Danazol19-norandrostenedione may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with 19-norandrostenedione.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione.Approved, Vet Approved
DienestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with 19-norandrostenedione.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.Approved
Dihydrotestosterone19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with 19-norandrostenedione.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione.Approved
EquolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.Approved
Etacrynic acid19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with 19-norandrostenedione.Experimental
Ethinyl EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with 19-norandrostenedione.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with 19-norandrostenedione.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with 19-norandrostenedione.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione.Approved
FenthionThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with 19-norandrostenedione.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with 19-norandrostenedione.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with 19-norandrostenedione.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with 19-norandrostenedione.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with 19-norandrostenedione.Experimental
Fluoxymesterone19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione.Approved, Investigational
FosaprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin.Approved
Furosemide19-norandrostenedione may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with GI-5005.Investigational
GLPG-049219-norandrostenedione may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with 19-norandrostenedione.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with 19-norandrostenedione.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with 19-norandrostenedione.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione.Approved, Investigational
Hydrochlorothiazide19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of 19-norandrostenedione can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione.Approved
IdelalisibThe serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with 19-norandrostenedione.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of 19-norandrostenedione.Approved
Indapamide19-norandrostenedione may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with 19-norandrostenedione.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione.Withdrawn
ItraconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione.Experimental
KetoconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with 19-norandrostenedione.Experimental
LopinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione.Approved, Investigational
LumacaftorThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione.Approved, Investigational
MagaldrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.Approved
Magnesium silicateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione.Approved
MefloquineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione.Approved
Mesterolone19-norandrostenedione may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione.Investigational, Withdrawn
MethallenestrilThe serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Methanesulfonyl Fluoride.Investigational
Methyclothiazide19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with 19-norandrostenedione.Approved, Vet Approved
Methyltestosterone19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Metoclopramide.Approved, Investigational
Metolazone19-norandrostenedione may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine.Approved
MitotaneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with 19-norandrostenedione.Experimental
MoxestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid.Approved, Investigational
Nandrolone19-norandrostenedione may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoate19-norandrostenedione may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione.Approved, Vet Approved
NefazodoneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione.Approved
NevirapineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with 19-norandrostenedione.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 19-norandrostenedione.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with 19-norandrostenedione.Vet Approved
Oxandrolone19-norandrostenedione may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Oxolinic acid.Experimental
Oxymetholone19-norandrostenedione may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with 19-norandrostenedione.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with 19-norandrostenedione.Approved, Investigational
PhenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pipemidic acid.Experimental
Piretanide19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with 19-norandrostenedione.Experimental
Polyestradiol phosphateThe serum concentration of 19-norandrostenedione can be increased when it is combined with Polyestradiol phosphate.Approved
Polythiazide19-norandrostenedione may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with 19-norandrostenedione.Experimental, Investigational
PrimidoneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with 19-norandrostenedione.Experimental
PromestrieneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with 19-norandrostenedione.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with 19-norandrostenedione.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol.Approved
Quinethazone19-norandrostenedione may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Approved, Experimental, Investigational
RifabutinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.Approved
SaquinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with 19-norandrostenedione.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 19-norandrostenedione.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione.Investigational
St. John's WortThe serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
Stanozolol19-norandrostenedione may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with 19-norandrostenedione.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with 19-norandrostenedione.Investigational
TecemotideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione.Approved, Withdrawn
TelithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with 19-norandrostenedione.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with 19-norandrostenedione.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione.Approved
Testosterone19-norandrostenedione may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone Propionate19-norandrostenedione may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.Approved
TiboloneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with 19-norandrostenedione.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.Approved
Torasemide19-norandrostenedione may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with 19-norandrostenedione.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trichlorfon.Vet Approved
Trichlormethiazide19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with 19-norandrostenedione.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 19-norandrostenedione.Approved
TromethamineThe bioavailability of 19-norandrostenedione can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
VoriconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarin19-norandrostenedione may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.Approved, Investigational
ZeranolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
  1. Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Schleipen B, Thevis M, Vollmer G, Zierau O: The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol Lett. 2008 Apr 1;177(3):198-204. doi: 10.1016/j.toxlet.2008.01.014. Epub 2008 Feb 2. [PubMed:18325697]
External Links
KEGG Compound
C14500
PubChem Compound
92834
PubChem Substance
46505377
ChemSpider
83803
ChEBI
34187
PDRhealth
PDRhealth Drug Page
Wikipedia
19-Norandrostenedione

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0454 mg/mLALOGPS
logP2.53ALOGPS
logP3.63ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)19.19ChemAxon
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.13 m3·mol-1ChemAxon
Polarizability31.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9723
Caco-2 permeable+0.7785
P-glycoprotein substrateSubstrate0.5551
P-glycoprotein inhibitor IInhibitor0.8097
P-glycoprotein inhibitor IINon-inhibitor0.6972
Renal organic cation transporterNon-inhibitor0.638
CYP450 2C9 substrateNon-substrate0.827
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.6816
CYP450 1A2 substrateNon-inhibitor0.8259
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.94
CYP450 2C19 inhibitorNon-inhibitor0.7094
CYP450 3A4 inhibitorNon-inhibitor0.8652
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7931
Ames testNon AMES toxic0.9189
CarcinogenicityNon-carcinogens0.9403
BiodegradationNot ready biodegradable0.9401
Rat acute toxicity1.6104 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7011
hERG inhibition (predictor II)Non-inhibitor0.7574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-00di-2950000000-5865fd40ca280de239b7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxo delta-4-steroids / 17-oxosteroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / Oxosteroid / 17-oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid (CHEBI:34187)

Drug created on July 24, 2007 14:36 / Updated on November 09, 2017 03:00